Abstract: Objective To identify the main active components in Shenbing decoction III and their targets and explore the mechanism by which Shenbing decoction III alleviates proteinuria in chronic kidney disease (CKD) based on network pharmacology. Methods The active components of Shenbing decoction III and their potential targets, along with the oral bioavailability and drug-like properties of each component were searched in the TCMSP database. The proteinuria-related targets were searched in the GeneCards database. The active component-target network was constructed using Cytoscape software, and the acquired information of the targets from ClueGO was used for enrichment analysis of the gene pathways. Results A total of 102 active components were identified from Shenbing decoction III. These active components acted on 126 targets, among which 69 were related to proteinuria. Enrichment analysis revealed fluid shear stress- and atherosclerosisrelated pathways as the highly significant pathways in proteinuria associated with CKD. Conclusion We preliminarily validated the prescription of Shenbing decoction III and obtained scientific evidence that supported its use for treatment of proteinuria in CKD. The findings in this study provide a theoretical basis for further study of the mechanism of Shenbing decoction III in the treatment of proteinuria in CKD.